Objective:

The article reports Sight Sciences’ announcement of OMNI Ultra’s commercial availability, its features, and its planned debut at the 2026 AAO Annual Meeting.

Approach:

• Device: OMNI Ultra combines canaloplasty and trabeculotomy in a single implant-free device designed to reduce intraocular pressure in adults with primary open-angle glaucoma.
• Procedure: The system enables canaloplasty around the circumference of Schlemm’s canal in a single pass, followed by trabeculotomy. The procedure is performed through a clear corneal microincision and can be used alone or with cataract surgery.
• Features: TruSync Plus automatically delivers viscoelastic during microcatheter advancement and retraction. Enhanced catheter visualization is intended to provide surgeons with greater visibility and control.

Key Findings:

• Sight Sciences announced OMNI Ultra’s commercial availability ahead of its debut at the 2026 AAO Annual Meeting in New Orleans.
• The system is designed to address three areas associated with resistance in the conventional aqueous outflow pathway: the trabecular meshwork, Schlemm’s canal, and the collector channels.
• Sight Sciences will demonstrate OMNI Ultra at booth #1237 during AAO, October 9–12, 2026.

Interpretation:

Zarmeena Vendal, a cataract and glaucoma surgeon and OMNI Ultra pre-launch user, said the system builds on the established OMNI platform and offers greater versatility and procedural flexibility.

Limitations:

• The provided article context describes product features and company announcements but reports no clinical outcome data or comparative evidence.

Conclusion:

At AAO, Sight Sciences will also preview Clearance Assistant Plus, a tool for its TearCare platform designed to support meibomian gland expression and eyelid debridement as part of treatment for meibomian gland dysfunction.

Sources:

• Article context provided by the user